BTG1 and metastatic malignant neoplasm: BTG1 expression was detectable in colorectal non-neoplastic mucosa (NNM, 3.8%, 18/475), adenoma (47.7%, 52/109), primary cancers (65.6%, 318/485), and metastatic cancers in lymph node (54.4%, 80/147) and liver (59.1%, 13/22), respectively.